Highest-materiality recent filing
Babeau will serve as Strategic Advisor through March 31, 2027, receiving base salary of CHF 1,260,012 and eligible for 2026 bonus.
PMI prepays €1.0B of term loan, reducing outstanding to €1.5B
Prepaid €1.0 billion ($1.1B) of the 5-year tranche of its senior unsecured term loan facility.
PM finalizes CFO Andolina's compensation: CHF 1.05M base, 125% IC, 275% equity target
Massimo Andolina appointed Group CFO effective Aug 1, 2026, replacing Emmanuel Babeau.
PM declares regular quarterly dividend of $1.47 per share
Dividend of $1.47 per common share declared, payable July 20, 2026.
PMI updates FY2026 EPS forecast to $7.18-$7.33; non-cash RBH impairment of ~$500M
Adjusted diluted EPS forecast $8.31-$8.46 (+10.2%-12.2% vs 2025); currency-adjusted growth 7.5%-9.5%.
Philip Morris appoints Massimo Andolina as Group CFO, effective August 1, 2026
Massimo Andolina promoted from President Europe Region to Group CFO, effective August 1, 2026, replacing Emmanuel Babeau.
PMI reports annual meeting results; all director nominees elected, shareholder proposal defeated
All 10 director nominees elected; 'for' votes ranged from 1.04B to 1.10B shares.
PMI annual meeting: FY2025 revenues >$40B; smoke-free $17B; targets best-in-class growth 2026-2028
Net revenues surpassed $40 billion in 2025, with ~$17 billion from smoke-free products.
PMI issues $1.5B in senior notes: $750M 4.125% due 2029, $750M 4.875% due 2036
Issued $750M of 4.125% Notes due 2029 and $750M of 4.875% Notes due 2036.
PMI Q1 adj EPS +16% to $1.96; IQOS becomes #1; updates FY adj EPS forecast for currency
Reported diluted EPS $1.56 (down 9.3% YoY); adjusted diluted EPS $1.96 (up 16.0%, 5.3% excluding currency).
PMI recasts 2025-2024 financials under new segments: Intl Smoke-Free, Intl Combustibles, U.S.
Segments effective Jan 1, 2026: International Smoke-Free, International Combustibles, U.S.; replaces four geographic segments.
Philip Morris declares regular quarterly dividend of $1.47 per share
Declared $1.47 per common share quarterly dividend, payable April 13, 2026.
PMI reaffirms 2026 adjusted EPS forecast of $8.38-$8.53, 11.1-13.1% growth
Reaffirmed 2026 reported diluted EPS $7.87-$8.02; adjusted diluted EPS $8.38-$8.53.
PMI furnishes CAGNY presentation slides; no specific financial data disclosed in filing
CEO Jacek Olczak and CFO Emmanuel Babeau presented at CAGNY on February 18, 2026.
PMI FY2025 adjusted EPS $7.54, +14.8%; smoke-free revenues surge; 2026-2028 targets set
Full-year adjusted diluted EPS of $7.54 grew 14.8% YoY, 14.2% currency-neutral.
PMI reports over $20B in U.S. investments since 2022; plans further spending
Over $20B invested in U.S. since 2022; $19B for Swedish Match acquisition, $1B additional in manufacturing & ops.
Philip Morris declares $1.47 quarterly dividend, payable Jan 14, 2026
Regular quarterly dividend of $1.47 per common share declared.
PMI enters $2B revolver due 2031, extends €1.5B facility to 2029
New $2B senior unsecured revolver signed Dec 11, 2025, expires Jan 29, 2031; replaces existing $2B facility due Feb 10, 2027.
PMI reaffirms 2025 adjusted EPS forecast of $7.39-$7.49 at Morgan Stanley conference
Reaffirmed full-year 2025 diluted EPS forecast of $7.39-$7.49, excluding $0.07 in adjustments.
PMI to redeem $1.7B of 4.875% Notes due Feb 2026 on Dec 4, 2025
Redemption of $1.7B aggregate principal of 4.875% Notes due Feb 13, 2026.
PMI to Reorganize into PMI International & U.S. Units; de Wilde Named CEO International
Effective Jan 1, 2026: PMI creates PMI International & U.S. business units; Jacek Olczak remains Group CEO.
PMI issues $3.5B in senior notes across five tranches; proceeds to refinance near-term debt
Issued $300M floating rate notes due 2028, $750M 3.875% due 2028, $750M 4.000% due 2030, $850M 4.250% due 2032, $850M 4.625% due 2035.
PMI Q3 adj. EPS $2.24 (+17.3% YoY); raises FY guidance; smoke-free rev +17.7%
Q3 reported diluted EPS $2.23 (+13.2% YoY); adjusted diluted EPS $2.24 (+17.3% YoY; +13.1% excl. currency).
Philip Morris raises quarterly dividend 8.9% to $1.47 per share
New quarterly dividend of $1.47 per share, up from $1.35 per share.
PMI reaffirms FY2025 adj. EPS growth 13-15%; Q3 ZYN offtake accelerates ~32%
Reaffirmed FY2025 reported EPS $7.24-$7.37, adj. EPS $7.43-$7.56 (growth 13-15%).
PMI Q2 adj. EPS $1.91 (+20%), record revenue, raises FY guidance
Reported diluted EPS $1.95 (+26.6% YoY); adjusted diluted EPS $1.91 (+20.1%, ex-currency +18.9%).
PMI held Europe Investor Focus Event; no financial data in filing
PMI held Europe Investor Focus Event on June 24, 2025; filing lacked operational or financial data.
PMI declares regular quarterly dividend of $1.35 per share, payable July 15
Board declared a regular quarterly dividend of $1.35 per common share on June 13, 2025.
PMI issues €1.0B in senior notes (2.75% due 2029, 3.25% due 2032)
€500M of 2.750% Notes due 2029 and €500M of 3.250% Notes due 2032 issued on June 6, 2025.
PMI reaffirms 2025 EPS guidance of $7.01-$7.14 reported, $7.36-$7.49 adjusted
Reaffirmed 2025 reported diluted EPS forecast of $7.01-$7.14.
All 11 director nominees elected with broker non-votes of ~164.8M; Kalpana Morparia received ~96.3M against, highest.
PMI annual meeting highlights smoke-free revenues near $15B, IQOS and ZYN anniversaries
CEO said smoke-free business reached almost $15B in net revenues in 2024.
PMI issues $2.5B in notes across four tranches for refinancing and general purposes
Issued $400M floating-rate notes due 2028 (SOFR+0.83%); $750M 4.125% notes due 2028; $750M 4.375% notes due 2030; $600M 4.875% notes due 2035.
PM Q1 2025: reported EPS $1.72 (+24.6%), adjusted EPS $1.69 (+12.7%); raises FY outlook
Reported diluted EPS $1.72 (+24.6%); adjusted diluted EPS $1.69 (+12.7%, or +17.3% excl. currency).
PMI updates segment reporting, recasts historical financials after Vectura sale
Following Dec 31, 2024 sale of Vectura, remaining Wellness & Healthcare moved into Europe segment.
Aggregate settlement CAD 32.5B (~USD 22.7B) funded by upfront cash and annual payments based on a % of net after-tax income.
PM declares regular quarterly dividend of $1.35 per share
Dividend of $1.35 per common share declared by Board of Directors.
PMI reaffirms 2025 EPS forecast at CAGNY; adjusted diluted EPS $7.04-$7.17, 7-9% YoY growth
Reaffirmed FY2025 reported diluted EPS forecast of $6.55-$6.68 and adjusted diluted EPS of $7.04-$7.17.
PMI CEO and CFO present at CAGNY conference; no material financial data in filing
Presentation slides furnished but lack specific financial numbers or guidance.
PMI: FY2024 adj. diluted EPS $6.57 (+9.3%); reported EPS $4.52; smoke-free 40% of net revenue
FY2024 reported diluted EPS $4.52; adjusted diluted EPS $6.57 (+9.3%, +15.6% currency-neutral); $6.01 before Canada impairment $1.49.
FDA authorizes all ZYN nicotine pouches, first authorized nicotine pouch in US
FDA granted marketing authorization for all 20 ZYN nicotine pouch variants (3 mg and 6 mg) marketed by Swedish Match.
PM completes sale of Vectura to Molex Asia Holdings; terms unchanged from Sep 17 announcement
Sale of Vectura Group Ltd. to Molex Asia Holdings Ltd. completed on Dec 31, 2024.
PMI enters €1.5B revolving credit facility due 2028 for corporate use
€1.5 billion (≈$1.6B) senior unsecured revolving credit facility signed Dec 17, 2024, effective Jan 29, 2025.
PM declares $1.35 quarterly dividend payable Jan 13, 2025
Quarterly dividend of $1.35 per common share declared.
Philip Morris prepays €3B 3-year term loan tranche due 2025
Prepaid approximately €3B ($3.2B) including principal and accrued interest under the 3-year tranche.
Philip Morris International issues $3B in senior notes across four tranches
Issued $750M each of 4.375% notes due 2027, 4.625% due 2029, 4.750% due 2031, and 4.900% due 2034.
Q3 2024 reported diluted EPS $1.97, up 49.2% YoY; adjusted diluted EPS $1.91, up 14.4% (or 18.0% ex-currency).
PMI's Canadian affiliate RBH included in proposed CAD 32.5B settlement of tobacco claims in Canada
RBH, ITL, JTIM would pay aggregate CAD 32.5B (~USD 23.5B) to settle tobacco claims; allocation among companies unresolved.
PMI agrees to sell Vectura Group to Molex for up to GBP 298M; expects ~$220M Q3 loss
Upfront cash consideration of GBP 150M (~$198M) plus up to GBP 148M in contingent milestone payments through 2039.
Philip Morris International raises quarterly dividend 3.8% to $1.35 per share
New quarterly dividend of $1.35 per share, up from $1.30; annualized rate $5.40.
the Board of Directors (the “Board”) of Philip Morris International Inc. (the “Company”) approved the appointment of Massimo Andolina, the Company’s current President, Europe Region, to the position of Group Chief Financial Officer, replacing Emmanuel Babeau, effective August 1, 2026.
replacing Emmanuel Babeau, effective August 1, 2026.
On May 18, 2026, the Board of Directors of Philip Morris International Inc. (the “Company”) approved the appointment of Massimo Andolina, the Company’s current President, Europe Region, as Group Chief Financial Officer, replacing Emmanuel Babeau, effective August 1, 2026.
Mr. Babeau will remain with the Company as Strategic Advisor to Jacek Olczak, Group CEO PMI through March 31, 2027 and to assist Mr. Andolina with his transition.
On September 13, 2023, Ms. Victoria Harker (age 59) was appointed to serve on the Board of Directors (the “Board”) of Philip Morris International Inc. (the “Company”), effective January 1, 2024.
Drago Azinovic, currently President, Middle East and Africa and PMI Duty Free Region, will leave the organization after a transition period in connection with the Company’s new regional structure and related senior management changes.
On January 5, 2023, Frederik Paulsen informed the Executive Chairman of the Board of Directors (the “Board”) of Philip Morris International Inc. (the “Company” or "PMI") that he will not stand for re-election to the Board at the Company’s 2023 Annual Meeting of Shareholders (the “2023 Annual Meeting”).
On January 10, 2023, Lucio A. Noto informed the Executive Chairman of the Board and the Company's Chief Executive Officer that he will also not stand for re-election to the Board at the Company’s 2023 Annual Meeting.
Frederic de Wilde, currently President, European Union Region, will be appointed President, South and Southeast Asia (SSEA), Commonwealth of Independent States (CIS), Middle East and Africa (MEA) Region.
On December 8, 2022, the Board of Directors (the “Board”) of Philip Morris International Inc. (the “Company”) approved the appointment of Jorge Insuasty as the full-time President, Vectura Fertin Pharma, effective January 1, 2023.
Drago Azinovic, currently President, Middle East and Africa and PMI Duty Free Region, will leave the organization after a transition period.
Ms. Dessislava Temperley (age 48) was appointed to the Board of Directors (the "Board") of Philip Morris International Inc. (the "Company") effective December 6, 2021.
Max materiality 0.90 · Median 0.55 · Most common event debt